NICE guidance on the use of carmustine wafers in high grade gliomas: a national study on variation in practice
Open Access
- 6 April 2012
- journal article
- research article
- Published by Taylor & Francis Ltd in British Journal of Neurosurgery
- Vol. 26 (3), 331-335
- https://doi.org/10.3109/02688697.2012.673651
Abstract
Background. Multidisciplinary team (MDT) working in oncology aims to improve outcomes for patients with cancer. One role is to ensure the implementation of best practice and National Institute for Health and Clinical Excellence (NICE) guidance. In this study, we have assessed the role of MDT in implementing the TA121 appraisal of the use of carmustine wafers in high grade gliomas. Methods. 296 patients with high-grade glioma suitable for maximal resection were recruited from 17 Neurosurgical Centres. The number of patients treated with carmustine wafers and reasons for not using this were recorded. Complications at 48 hours post-operatively and at 6 weeks post-radiotherapy were recorded. Results. 94/296 (32%) of suitable patients received carmustine wafers. In 55% of cases carmustine was not used due to either surgeon preference or a lack of an MDT decision. There was no increased complication rate with carmustine use at either 48 hours post-surgery or at 6 weeks post radiotherapy. Use of carmustine wafers did not decrease access to and use of chemoradiotherapy. Conclusions. One third of patients suitable for carmustine wafers received them. Their use was neither associated with more frequent complications, nor decreased use of chemoradiotherapy. Implementation of NICE TA121 Guidance is extremely variable in different MDTs across the United Kingdom.Keywords
This publication has 14 references indexed in Scilit:
- Retrospective Comparison of Chemoradiotherapy Followed by Adjuvant Chemotherapy, With or Without Prior Gliadel Implantation (Carmustine) After Initial Surgery in Patients With Newly Diagnosed High-Grade GliomasInternational Journal of Radiation Oncology*Biology*Physics, 2012
- Chemotherapy wafers for high grade gliomaCochrane Database of Systematic Reviews, 2011
- First-line treatment of malignant glioma with carmustine implants followed by concomitant radiochemotherapy: a multicenter experienceNeurosurgical Review, 2010
- Biodegradable Carmustine Wafers (Gliadel) Alone or in Combination with Chemoradiotherapy: The French ExperienceAnnals of Surgical Oncology, 2010
- Gliadel (BCNU) wafer plus concomitant temozolomide therapy after primary resection of glioblastoma multiformeJournal of Neurosurgery, 2009
- The 2007 WHO Classification of Tumours of the Central Nervous SystemActa Neuropathologica, 2007
- Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trialThe Lancet Oncology, 2006
- Radiotherapy plus Concomitant and Adjuvant Temozolomide for GlioblastomaNew England Journal of Medicine, 2005
- Early Postoperative Magnetic Resonance Imaging after Resection of Malignant GliomaNeurosurgery, 1994
- Early Postoperative Magnetic Resonance Imaging after Resection of Malignant Glioma: Objective Evaluation of Residual Tumor and Its Influence on Regrowth and PrognosisNeurosurgery, 1994